Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2021 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST

HANOVER, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
October 12, 2021 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis

HANOVER, MD, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
September 16, 2021 11:05 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update

HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
September 16, 2021 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
August 23, 2021 16:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27

HANOVER, MD, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
August 12, 2021 17:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update

Adds fourth clinical asset, RX-3117, and targets major milestones in the second half of 2021 HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a...
August 06, 2021 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST

HANOVER, Md., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
August 04, 2021 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer

Processa’s Phase 1b open label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for...
July 27, 2021 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET

HANOVER, MD, July 27, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event...
July 06, 2021 08:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET

HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right